Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.79
IPCI's Cash-to-Debt is ranked lower than
68% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. IPCI: 1.79 )
Ranked among companies with meaningful Cash-to-Debt only.
IPCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: No Debt Max: No Debt
Current: 1.79
Equity-to-Asset 0.11
IPCI's Equity-to-Asset is ranked lower than
89% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IPCI: 0.11 )
Ranked among companies with meaningful Equity-to-Asset only.
IPCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.66 Max: 1
Current: 0.11
-1.36
1
Piotroski F-Score: 4
Altman Z-Score: -9.92
Beneish M-Score: -1.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -331.09
IPCI's Operating Margin % is ranked lower than
69% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. IPCI: -331.09 )
Ranked among companies with meaningful Operating Margin % only.
IPCI' s Operating Margin % Range Over the Past 10 Years
Min: -9455.14  Med: -438.41 Max: -40.29
Current: -331.09
-9455.14
-40.29
Net Margin % -345.10
IPCI's Net Margin % is ranked lower than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. IPCI: -345.10 )
Ranked among companies with meaningful Net Margin % only.
IPCI' s Net Margin % Range Over the Past 10 Years
Min: -5735.51  Med: -451.45 Max: -43.97
Current: -345.1
-5735.51
-43.97
ROE % -7199.11
IPCI's ROE % is ranked lower than
99.99% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. IPCI: -7199.11 )
Ranked among companies with meaningful ROE % only.
IPCI' s ROE % Range Over the Past 10 Years
Min: -7199.11  Med: -233.36 Max: -103.24
Current: -7199.11
-7199.11
-103.24
ROA % -172.16
IPCI's ROA % is ranked lower than
93% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. IPCI: -172.16 )
Ranked among companies with meaningful ROA % only.
IPCI' s ROA % Range Over the Past 10 Years
Min: -341.43  Med: -102.99 Max: -64.64
Current: -172.16
-341.43
-64.64
ROC (Joel Greenblatt) % -510.25
IPCI's ROC (Joel Greenblatt) % is ranked lower than
54% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. IPCI: -510.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IPCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7954.63  Med: -544.16 Max: -235.67
Current: -510.25
-7954.63
-235.67
3-Year Revenue Growth Rate 11.70
IPCI's 3-Year Revenue Growth Rate is ranked higher than
61% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. IPCI: 11.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IPCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 236.7
Current: 11.7
0
236.7
3-Year EBITDA Growth Rate -5.70
IPCI's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IPCI: -5.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IPCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.5 Max: 44.9
Current: -5.7
0
44.9
3-Year EPS without NRI Growth Rate -5.70
IPCI's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. IPCI: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IPCI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.45 Max: 63.9
Current: -5.7
0
63.9
GuruFocus has detected 3 Warning Signs with IntelliPharmaCeutics International Inc $IPCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IPCI's 30-Y Financials

Financials (Next Earnings Date: 2017-07-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:NAS:ZSAN, NAS:CFRX, NAS:CASI, NAS:EIGR, NAS:CTIC, NAS:AGLE, NAS:FLKS, OTCPK:ONCYF, NAS:GLMD, OTCPK:PMCB, NAS:KMPH, OTCPK:FENCF, NAS:NVIV, OTCPK:ANTB, NAS:LPTX, OTCPK:TBQBF, NAS:GTXI, NAS:SRRA, OTCPK:LVCLY, NAS:CXRX » details
Traded in other countries:IPCI.Canada, I4A.Germany,
Headquarter Location:Canada
IntelliPharmaCeutics International Inc is a pharmaceutical company. The Company is engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

IntelliPharmaCeutics International Inc was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, it has developed several drug delivery systems and a pipeline of products and product candidates in various stages of development, including ANDAs filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix technologies are applied to the development of both existing and new pharmaceuticals across a range of therapeutic classes. Its scientists have developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a wide range of pharmaceuticals. These systems include several core technologies, which enable them to flexibly respond to a wide range of drug attributes and patient requirements, producing a desired controlled-release effect. The platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle and nPODDDS. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The sales of its products by its licensees outside the United States and Canada will be subject to regulatory requirements governing the testing, registration and marketing of pharmaceuticals, which vary widely from country to country.

Top Ranked Articles about IntelliPharmaCeutics International Inc

Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®
Intellipharmaceutics Reports Director Election Results
Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Extended-Release Oxycodone
Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”

TORONTO, March 16, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I)  ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that, effective at the opening of trading on Monday, March 20, 2017, common shares of the Company will commence trading on the Toronto Stock Exchange (“TSX”) under the symbol “IPCI”.
With this change, the Company’s TSX trading symbol is now harmonized with the Nasdaq stock market symbol.  This symbol change does not require any action by current shareholders. There is no change in the company's name, no change in its CUSIP number and no consolidation of capital. About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (some of which have received U.S. Food and Drug Administration ("FDA") approval) and product candidates in various stages of development, including abbreviated new drug applications ("ANDAs") filed with the FDA (and one Abbreviated New Drug Submission filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. Intellipharmaceutics also has New Drug Application (“NDA”) 505(b)(2) specialty drug product candidates in its development pipeline. These include RexistaTM (abuse deterrent oxycodone hydrochloride extended release tablets), based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™ XR (pregabalin extended-release capsules). Our current development effort is increasingly directed towards improved difficult-to-develop controlled-release drugs which follow an NDA 505(b)(2) regulatory pathway. The Company has increased its research and development emphasis towards new product development, facilitated by the 505(b)(2) regulatory pathway, by advancing the product development program for both RexistaTM and Regabatin™.  The 505(b)(2) pathway (which relies in part upon the approving agency’s findings for a previously approved drug) both accelerates development timelines and reduces costs in comparison to NDAs for new chemical entities. An advantage of our strategy for development of NDA 505(b)(2) drugs is that our product candidates can, if approved for sale by the FDA, potentially enjoy an exclusivity period which may provide for greater commercial opportunity relative to the generic ANDA route. Cautionary Statement Regarding Forward-Looking Information Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “plans to,” “anticipates,” “believes,” “estimates,” “predicts,” “confident”, “potential,” “continue,” “intends,” “could,” or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, on capital availability, the potential dilutive effects of any future financing and the expected use of any proceeds from any offering of our securities, our ability to maintain compliance with the continued listing requirements of the principal markets on which our securities are traded, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates and the difficulty in predicting the timing and results of any product launches, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property for our drug delivery technologies, products and product candidates, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, delays that may be caused by changing regulatory requirements, the difficulty in predicting the timing of regulatory approval and launch of competitive products, the difficulty in predicting the impact of competitive products on volume, pricing, rebates and other allowances, the inability to forecast wholesaler demand and/or wholesaler buying patterns, the seasonal fluctuation in the numbers of prescriptions written for our Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules which may produce substantial fluctuations in revenues, the timing and amount of insurance reimbursement for our products, changes in laws and regulations affecting the conditions required by the FDA for approval, testing and labelling of drugs including abuse or overdose deterrent properties, and changes affecting how opioids are regulated and prescribed by physicians, changes in laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third party sourced products and materials, challenges related to the development, commercialization, technology transfer, scale-up, and/or process validation of manufacturing processes for our products or product candidates, the manufacturing capacity of third-party manufacturers that we may use for our products, the successful compliance with FDA, Health Canada and other governmental regulations applicable to the Company and its third party manufacturers' facilities, products and/or businesses, difficulties, delays or changes in the FDA approval process or test criteria for ANDAs and NDAs, challenges in securing final FDA approval for our product candidates including, RexistaTM in particular, if a patent infringement suit is filed against us, which could delay the FDA’s final approval of such product candidates, healthcare reform measures could hinder or prevent the commercial success of our products and product candidates, the FDA may not approve requested product labelling for our product candidate(s) having abuse-deterrent properties, risks associated with cyber-security and the potential for vulnerability of the digital information of the Company or a current and/or future drug development or commercialization partner of the Company and risks arising from the ability and willingness of our third-party commercialization partners to provide documentation that may be required to support information on revenues earned by us from those commercialization partners. Additional risks and uncertainties relating to the Company and our business can be found in the “Risk Factors” section of our latest annual information form, our latest Form 20-F, and our latest Form F-3 (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on www.sedar.com and www.sec.gov. The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Trademarks used herein are the property of their respective holders.
Company Contact:
Intellipharmaceutics International Inc.
Domenic Della Penna
Chief Financial Officer
416-798-3001 ext. 106
[email protected]

Investor Contact:
ProActive Capital
Kirin Smith
646-863-6519
[email protected]

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 19.08
IPCI's Forward PE Ratio is ranked lower than
81% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. IPCI: 19.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 69.74
IPCI's PB Ratio is ranked lower than
99% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. IPCI: 69.74 )
Ranked among companies with meaningful PB Ratio only.
IPCI' s PB Ratio Range Over the Past 10 Years
Min: 6.86  Med: 16.53 Max: 551.11
Current: 69.74
6.86
551.11
PS Ratio 19.78
IPCI's PS Ratio is ranked lower than
70% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. IPCI: 19.78 )
Ranked among companies with meaningful PS Ratio only.
IPCI' s PS Ratio Range Over the Past 10 Years
Min: 6.01  Med: 22.68 Max: 4290
Current: 19.78
6.01
4290
Current Ratio 1.12
IPCI's Current Ratio is ranked lower than
82% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. IPCI: 1.12 )
Ranked among companies with meaningful Current Ratio only.
IPCI' s Current Ratio Range Over the Past 10 Years
Min: 0.25  Med: 4.88 Max: 94.99
Current: 1.12
0.25
94.99
Quick Ratio 1.03
IPCI's Quick Ratio is ranked lower than
78% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. IPCI: 1.03 )
Ranked among companies with meaningful Quick Ratio only.
IPCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.25  Med: 4.6 Max: 94.99
Current: 1.03
0.25
94.99
Days Inventory 14.48
IPCI's Days Inventory is ranked lower than
99.99% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. IPCI: 14.48 )
Ranked among companies with meaningful Days Inventory only.
IPCI' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14.48
Current: 14.48
0
14.48
Days Sales Outstanding 133.87
IPCI's Days Sales Outstanding is ranked lower than
60% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. IPCI: 133.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.5  Med: 42.08 Max: 352.81
Current: 133.87
0.5
352.81
Days Payable 182.95
IPCI's Days Payable is ranked lower than
99.99% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. IPCI: 182.95 )
Ranked among companies with meaningful Days Payable only.
IPCI' s Days Payable Range Over the Past 10 Years
Min: 30.4  Med: 39.45 Max: 182.95
Current: 182.95
30.4
182.95

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.60
IPCI's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. IPCI: -11.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.7  Med: -22.55 Max: -10.6
Current: -11.6
-120.7
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 64.67
IPCI's Price-to-Tangible-Book is ranked lower than
98% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. IPCI: 64.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IPCI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.02  Med: 0.61 Max: 286.67
Current: 64.67
0.02
286.67
Price-to-Median-PS-Value 0.87
IPCI's Price-to-Median-PS-Value is ranked lower than
66% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. IPCI: 0.87 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.46 Max: 400
Current: 0.87
0.29
400
Earnings Yield (Greenblatt) % -16.42
IPCI's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. IPCI: -16.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -671.7  Med: 0 Max: 0
Current: -16.42
-671.7
0

More Statistics

Revenue (TTM) (Mil) $2.92
EPS (TTM) $ -0.36
Beta0.76
Short Percentage of Float9.11%
52-Week Range $1.41 - 3.35
Shares Outstanding (Mil)30.39

Analyst Estimate

Nov17 Nov18 Nov19
Revenue (Mil $) 20 33 103
EPS ($) 0.10 0.27 1.66
EPS without NRI ($) 0.10 0.27 1.66
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IPCI

Headlines

Articles On GuruFocus.com
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Rep May 26 2017 
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Phar May 24 2017 
Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR® May 10 2017 
Intellipharmaceutics Reports Director Election Results Apr 18 2017 
Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Apr 10 2017 
Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” Mar 16 2017 
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR Feb 24 2017 
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydroch Feb 02 2017 
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 

More From Other Websites
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to... May 26 2017
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par... May 24 2017
Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR® May 10 2017
Intellipharmaceutics Reports Director Election Results Apr 18 2017
Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q1, 2017 By the Numbers :... Apr 14 2017
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected Apr 13 2017
Intellipharmaceutics reports 1Q loss Apr 11 2017
Intellipharmaceutics Announces First Quarter 2017 Results Apr 11 2017
Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent... Apr 10 2017
Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: 2016 By the Numbers : March... Mar 22 2017
Nektar Pharma Opioid Drug Shows Promise In Phase 3 Mar 20 2017
Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” Mar 16 2017
Monday Movers In Biotech: Cempra Inc (CEMP) And IntelliPharmaCeutics Intl Inc (USA) (IPCI) Feb 27 2017
Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and... Feb 27 2017
Intellipharmaceutics Painkiller Qualifies for FDA Review Feb 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)